A Study To verify the efficacy of ROsuvastatin 2.5 mg as an aggressive lipid lowering therapy for hypercholesterolemia-1
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-UMIN000000812
- Lead Sponsor
- Graduate Scholl of Medicine, the University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Patients with Severe hypertension (SBP>=180 mmHg or DBP>=110 mmHg) 2) Patients with type I diabetes 3) Patients with familial hypercholesterolemia 4) Patients with fasting serum TG>=400 mg/dL 5) Patients who have experienced cerebrovascular diseases within 3 months 6) Patients with serious heart failure (NYHA class III to IV) 7) Patients undergoing PTCA/CABG during the study period 8) Patients with active hepatic disease (ALT or AST>100 IU/L or total bilirubin> 2.5 mg/dL) 9) Patients with renal disorder (Cr>=2.0 mg/dL or Ccr<30 mL/min/1.73 m2) 10) Patients with CK>1000 IU/L 11) Pregnant women, impregnable women, or those who hope to be pregnant during the study period 12) Patients with hypothyroidism, hereditary muscular diseases (muscular dystrophy, etc.) or familial history of these diseases. Patients with history of drug-related muscular disorder 13) Patients with drug abuse or alcoholism 14) Patients who use prohibited concomitant drugs* or who might use such drugs during the study period 15) Patients who are ineligible in the opinion of the investigator *Statines, fibrates, anion exchange resin, cholesterol absorption inhibitors, probucol, nicotine acids, phytosterol, other anti hypercholesterolaemia drugs, immune suppressing drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method